Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers.
暂无分享,去创建一个
[1] J. T. Zilfou,et al. Circumvention of P-glycoprotein-mediated Multiple Drug Resistance by Phosphorylation Modulators Is Independent of Protein Kinases (*) , 1995, The Journal of Biological Chemistry.
[2] R. Fine,et al. Partial Inhibition of Multidrug Resistance by Safingol Is Independent of Modulation of P-glycoprotein Substrate Activities and Correlated with Inhibition of Protein Kinase C (*) , 1995, The Journal of Biological Chemistry.
[3] M. Raschack,et al. Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. , 1995, Biochemical pharmacology.
[4] C. Higgins,et al. The ABC of channel regulation , 1995, Cell.
[5] S. Dei,et al. Reversal of multidrug resistance by verapamil analogues. , 1995, Biochemical pharmacology.
[6] W. Wilson,et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] C. Cordon-Cardo,et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] F. Ognibene,et al. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] W. Wilson,et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] K. Osann,et al. Comparison of cyclosporin A, verapamil, PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias. , 1995, Leukemia research.
[11] J. Robert,et al. Azelastine and flezelastine as reversing agents of multidrug resistance: pharmacological and molecular studies. , 1995, Biochemical pharmacology.
[12] T. Tsuruo,et al. Novel dithiane analogues of tiapamil with high activity to overcome multidrug resistance in vitro. , 1995, Biochemical pharmacology.
[13] V. Ling,et al. Reconstitution of Drug Transport by Purified P-glycoprotein (*) , 1995, The Journal of Biological Chemistry.
[14] G Ecker,et al. Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance. , 1995, Journal of medicinal chemistry.
[15] N. Dodic,et al. Synthesis and activity against multidrug resistance in Chinese hamster ovary cells of new acridone-4-carboxamides. , 1995, Journal of medicinal chemistry.
[16] A. Newland,et al. Circumvention of P‐glycoprotein‐mediated drug resistance in human leukaemic cells by non‐immunosuppressive cyclosporin D analogue, SDZ PSC 833 , 1995, British journal of haematology.
[17] W. Hait,et al. Involvement of phospholipase C in heat-shock-induced phosphorylation of P-glycoprotein in multidrug resistant human breast cancer cells. , 1995, Biochemical and biophysical research communications.
[18] B. Sikic,et al. Drug resistance in clinical oncology and hematology. Introduction. , 1995, Hematology/oncology clinics of North America.
[19] J. Ford,et al. Modulators of multidrug resistance. Preclinical studies. , 1995, Hematology/oncology clinics of North America.
[20] B. Sikic,et al. Clinical studies with modulators of multidrug resistance. , 1995, Hematology/oncology clinics of North America.
[21] R. Arceci,et al. Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype. , 1995, British Journal of Cancer.
[22] I. Pastan,et al. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. , 1995, Cancer research.
[23] C. Higgins,et al. Interaction of tamoxifen with the multidrug resistance P-glycoprotein. , 1995, British Journal of Cancer.
[24] I. Pastan,et al. Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin. , 1994, Molecular pharmacology.
[25] C. Smith,et al. Cryptophycin: a new antimicrotubule agent active against drug-resistant cells. , 1994, Cancer research.
[26] T. Tsuruo,et al. Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies. , 1994, Blood.
[27] P. Gros,et al. Structurally distinct MDR modulators show specific patterns of reversal against P-glycoproteins bearing unique mutations at serine939/941. , 1994, Biochemistry.
[28] P. Gros,et al. Functional expression of P-glycoproteins in secretory vesicles. , 1994, The Journal of biological chemistry.
[29] D. Clarke,et al. Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein. , 1994, The Journal of biological chemistry.
[30] C. Higgins. P-Glycoprotein: To flip or not to flip? , 1994, Current Biology.
[31] V. Ling,et al. ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells. , 1994, The Journal of biological chemistry.
[32] S. Bicknell,et al. Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft. , 1994, Biochemical pharmacology.
[33] F. Leonessa,et al. Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170,000 glycoprotein (gp170) binding studies. , 1994, Cancer research.
[34] R. Boer,et al. Influence of dexniguldipine-HC1 on rhodamine-123 accumulation in a multidrug-resistant leukaemia cell line: comparison with other chemosensitisers. , 1994, European journal of cancer.
[35] C. Smith,et al. Reversal of multiple drug resistance by tolyporphin, a novel cyanobacterial natural product. , 1994, Oncology research.
[36] W. Hait,et al. Functional role of phosphorylation of the multidrug transporter (P-glycoprotein) by protein kinase C in multidrug-resistant MCF-7 cells. , 1994, Oncology research.
[37] D. Y. Thomas,et al. Functional expression of P-glycoprotein in Saccharomyces cerevisiae confers cellular resistance to the immunosuppressive and antifungal agent FK520. , 1994, Molecular and cellular biology.
[38] P. Gros,et al. Functional expression of P-glycoprotein encoded by the mouse mdr3 gene in yeast cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[39] F. Sharom,et al. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. , 1993, The Journal of biological chemistry.
[40] P. Gros,et al. Functional expression of mouse mdr1 in Escherichia coli. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[41] C. Vergely,et al. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. , 1993, Cancer research.
[42] A. Harris,et al. Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites. , 1993, British Journal of Cancer.
[43] M. Stevenson,et al. Inducers of the heat shock response stimulate phospholipase C and phospholipase A2 activity in mammalian cells , 1993, Journal of cellular physiology.
[44] Y. Cheng,et al. BIBW 22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport. , 1993, Cancer research.
[45] F. Loor,et al. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. , 1993, Journal of the National Cancer Institute.
[46] S. Carmeli,et al. Scytophycins, novel microfilament-depolymerizing agents which circumvent P-glycoprotein-mediated multidrug resistance. , 1993, Cancer research.
[47] D. Clarke,et al. Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein. , 1993, The Journal of biological chemistry.
[48] M. Reiss,et al. Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. , 1993, Biochemical pharmacology.
[49] D. Fabbro,et al. Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha. , 1993, The Journal of biological chemistry.
[50] I. Pastan,et al. Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.
[51] R Hori,et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. , 1992, The Journal of biological chemistry.
[52] G. C. Yeh,et al. A new functional role for P-glycoprotein: efflux pump for benzo(alpha)pyrene in human breast cancer MCF-7 cells. , 1992, Cancer research.
[53] I. Pastan,et al. Characterization of the azidopine and vinblastine binding site of P-glycoprotein. , 1992, The Journal of biological chemistry.
[54] M. Weir,et al. EVIDENCE THAT THE ANTIPROLIFERATIVE EFFECT OF VERAPAMIL ON AFFERENT AND EFFERENT IMMUNE RESPONSES IS INDEPENDENT OF CALCIUM CHANNEL INHIBITION , 1992, Transplantation.
[55] S. Howell,et al. Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro. , 1992, Cancer research.
[56] S. Takao,et al. Effect of a dihydropyridine analogue, 2-[benzyl(phenyl)amino]ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo- 1,3,2-dioxaphosphorinan-2-yl)-1-(2-morpholinoethyl)-4-(3-nitrophenyl)-3 -pyridinecarboxylate on reversing in vivo resistance of tumor cells to adriamycin. , 1992, Cancer research.
[57] M. Dietel,et al. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. , 1992, Biochemical pharmacology.
[58] S. Gollapudi,et al. Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport. , 1992, Cancer letters.
[59] A. Pourtier-Manzanedo,et al. SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance. , 1992, British Journal of Cancer.
[60] W. Hait,et al. Structure-activity relationships of phenothiazines and related drugs for inhibition of protein kinase C. , 1991, Molecular pharmacology.
[61] G. Laurent,et al. Reversal of multidrug resistance by calcium channel blocker SR33557 without photoaffinity labeling of P-glycoprotein. , 1991, The Journal of biological chemistry.
[62] I. Tamai,et al. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. , 1991, The Journal of biological chemistry.
[63] A. Pourtier-Manzanedo,et al. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. , 1991, Experimental cell research.
[64] E. Krebs,et al. Consensus sequences as substrate specificity determinants for protein kinases and protein phosphatases. , 1991, The Journal of biological chemistry.
[65] D. Fan,et al. In vitro model for intrinsic drug resistance: effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells. , 1991, Molecular pharmacology.
[66] L. Takemoto,et al. Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine. , 1991, The Journal of biological chemistry.
[67] T. Furukawa,et al. Glycosylation of P-glycoprotein in a multidrug-resistant KB cell line, and in the human tissues. , 1991, Biochimica et biophysica acta.
[68] I. Fidler,et al. Transient enhancement of multidrug resistance by the bile acid deoxycholate in murine fibrosarcoma cells in vitro. , 1991, Biochemical pharmacology.
[69] P. Gros,et al. Multidrug resistance: a novel class of membrane-associated transport proteins is identified. , 1991, Cancer investigation.
[70] B. Kemp,et al. Protein kinase recognition sequence motifs. , 1990, Trends in biochemical sciences.
[71] J. M. Ford,et al. Pharmacology of drugs that alter multidrug resistance in cancer. , 1990, Pharmacological reviews.
[72] D. Cohen,et al. Differential transport properties of two mdr gene products are distinguished by progesterone. , 1990, The Journal of biological chemistry.
[73] T. Chambers,et al. Correlation of protein kinase C translocation, P-glycoprotein phosphorylation and reduced drug accumulation in multidrug resistant human KB cells. , 1990, Biochemical and biophysical research communications.
[74] J. Zalcberg,et al. Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. , 1990, Cancer research.
[75] T. Chambers,et al. Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. , 1990, The Journal of biological chemistry.
[76] A. Harris,et al. Enhancement of Adriamycin cytotoxicity in a multidrug resistant Chinese hamster ovary (CHO) subline, CHO-Adrr, by toremifene and its modulation by alpha 1 acid glycoprotein. , 1990, European journal of cancer.
[77] I. Pastan,et al. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. , 1990, Cancer research.
[78] S. Kaye,et al. The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific. , 1990, Biochemical pharmacology.
[79] P. Hiestand,et al. Overcoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives. , 1989, British Journal of Cancer.
[80] S. Keyes,et al. Enhancement of anthracycline growth inhibition in parent and multidrug-resistant Chinese hamster ovary cells by cyclosporin A and its analogues. , 1989, Cancer research.
[81] A. W. Boersma,et al. Effects of cyclosporin a and verapamil on the intracellular daunorubicin accumulation in chinese hamster ovary cells with increasing levels of drug‐resistance , 1989, International journal of cancer.
[82] I. Pastan,et al. Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin-induced leukopenia , 1989, Molecular and cellular biology.
[83] B. Ryffel,et al. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. , 1989, Molecular pharmacology.
[84] T. Tsuruo,et al. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. , 1989, Cancer research.
[85] C. Benz,et al. Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] S. Howell,et al. Dipyridamole enhancement of etoposide sensitivity. , 1989, Cancer research.
[87] R. Johnstone,et al. Enhanced efflux of [3H]vinblastine from Chinese hamster ovary cells transfected with a full-length complementary DNA clone for the mdr1 gene. , 1989, Cancer research.
[88] H L Pearce,et al. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[89] S. Howell,et al. Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamole. , 1989, Cancer research.
[90] G. Duggin,et al. Cyclosporin A inhibits protein kinase C activity: a contributing mechanism in the development of nephrotoxicity? , 1989, Biochemical and biophysical research communications.
[91] T. Tsuruo,et al. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement. , 1989, Cancer research.
[92] Robert,et al. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. , 1989, The Journal of biological chemistry.
[93] W. Hait,et al. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. , 1989, Molecular pharmacology.
[94] M. Morin,et al. Human multidrug resistant KB cells overexpress protein kinase C: involvement in drug resistance. , 1989, Cancer communications.
[95] M. B. Meyers. Protein phosphorylation in multidrug resistant Chinese hamster cells. , 1989, Cancer communications.
[96] A. Safa. Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[97] W. T. Beck,et al. Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. , 1988, Biochemical and biophysical research communications.
[98] D. Housman,et al. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[99] W. Mellado,et al. Azidopine photoaffinity labeling of multidrug resistance-associated glycoproteins. , 1988, Biochemical pharmacology.
[100] H L Pearce,et al. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. , 1988, Molecular pharmacology.
[101] H. Parnes,et al. Studies of high-dose megestrol acetate: potential applications in cachexia. , 1988, Seminars in oncology.
[102] C. Peterson,et al. D‐verapamil and L‐verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro , 1988, International journal of cancer.
[103] I. Pastan,et al. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. , 1988, Molecular pharmacology.
[104] R. Fine,et al. Phorbol esters induce multidrug resistance in human breast cancer cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[105] W. Mellado,et al. Phosphorylation of the multidrug resistance associated glycoprotein. , 1987, Biochemistry.
[106] N. Fox,et al. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. , 1987, British Journal of Cancer.
[107] A. Safa,et al. Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. , 1987, The Journal of biological chemistry.
[108] T. Tsuruo,et al. Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters. , 1987, Cancer research.
[109] I. Pastan,et al. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[110] Y. Ostchega,et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] I. Pastan,et al. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. , 1987, The Journal of biological chemistry.
[112] Y. Cheng,et al. Transient protection of cultured human cells against antitumor agents by 12-O-tetradecanoylphorbol-13-acetate. , 1987, Cancer research.
[113] D. Housman,et al. Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins , 1986, Cell.
[114] Michael M. Gottesman,et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells , 1986, Cell.
[115] D. Housman,et al. Isolation and expression of a complementary DNA that confers multidrug resistance , 1986, Nature.
[116] S. Gupta,et al. Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. , 1986, British journal of cancer.
[117] G. Hahn,et al. Rapid increases in inositol trisphosphate and intracellular Ca++ after heat shock. , 1986, Biochemical and biophysical research communications.
[118] R. Ganapathi,et al. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine. , 1986, Biochemical pharmacology.
[119] B. Chauffert,et al. Amiodarone-induced enhancement of doxorubicin and 4'-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. , 1986, Cancer research.
[120] H. Hidaka,et al. An inhibitor of protein kinase C, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine(H-7) inhibits TPA-induced reduction of vincristine uptake from P388 murine leukemic cell. , 1986, Leukemia research.
[121] J. Grem,et al. Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole. , 1985, Cancer research.
[122] D. Kessel,et al. Promotion of daunorubicin uptake and toxicity by the calcium antagonist tiapamil and its analogs. , 1985, Cancer treatment reports.
[123] I. Weinstein,et al. Inhibition of protein kinase C by tamoxifen. , 1985, Cancer research.
[124] P. Molinoff,et al. Assay of dopamine receptors with [alpha-3H]flupenthixol. , 1985, The Journal of pharmacology and experimental therapeutics.
[125] R. Ganapathi,et al. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells. , 1984, Cancer research.
[126] T. Tsuruo,et al. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. , 1984, Cancer research.
[127] Z. Fuks,et al. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. , 1984, Cancer research.
[128] H. Rahamimoff,et al. Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells. , 1984, British Journal of Cancer.
[129] S. Drake,et al. Potentiation of methotrexate toxicity by dipyridamole. , 1984, Cancer research.
[130] J. Riordan,et al. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. , 1983, Science.
[131] T. Tsuruo,et al. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. , 1983, Cancer research.
[132] T. Tsuruo,et al. Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. , 1983, Cancer research.
[133] V. Jordan,et al. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. , 1983, Cancer research.
[134] T. Tsuruo,et al. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. , 1982, Cancer research.
[135] W. T. Beck,et al. Continued expression of vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase. , 1982, Cancer research.
[136] T. Tsuruo,et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.
[137] R. Schatzman,et al. Phospholipid-sensitive calcium-dependent protein kinase: inhibition by antipsychotic drugs. , 1981, Biochemical and biophysical research communications.
[138] Y. Nishizuka,et al. Inhibitory action of chlorpromazine, dibucaine, and other phospholipid-interacting drugs on calcium-activated, phospholipid-dependent protein kinase. , 1980, The Journal of biological chemistry.
[139] T. Skovsgaard. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. , 1978, Cancer research.
[140] T. Crow,et al. MECHANISM OF THE ANTIPSYCHOTIC EFFECT IN THE TREATMENT OF ACUTE SCHIZOPHRENIA , 1978, The Lancet.
[141] J. Till,et al. Modulation of drug permeability in Chinese hamster ovary cells. Possible role for phosphorylation of surface glycoproteins. , 1977, Biochimica et biophysica acta.
[142] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[143] M. Post,et al. Stereoselective blockade of the dopamine receptor and the X-ray structures of α and β-flupenthixol , 1975, Nature.
[144] K. Danø. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. , 1973, Biochimica et biophysica acta.
[145] J. L. Biedler,et al. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. , 1970, Cancer research.